2023
Wednesday Wed
Event Sponsors
CDCM 7th Annual Symposium
Registration is now open!
Join us for the CDCM's 7th annual symposium and learn about new cell, gene, and regenerative medicine discoveries, pre-clinical development and clinical trials of curative medicines, and challenges with bringing these cures to patients to meet unmet medical needs. Exploration and discussion of these topics will be held at this one-day conference for clinicians, basic scientists, patient advocates, translational investigators, and biotech and pharmaceutical experts. More than 700 people are expected to attend, including a growing number of international participants from Europe, Asia Pacific, and the Middle East. This year, we are offering virtual participation as well as a return to in-person attendance!
The symposium is now over. Thank you all to those who attended!
Each year, the CDCM hosts an annual symposium to engage in scientific discussion about new discoveries and developments in the cell and gene therapy field. The 7th annual symposium will host speakers to present on topics related to the field, including new cell, gene, and regenerative medicine discoveries; pre-clinical development and clinical trials of curative medicines; and challenges with bringing these cures to patients with unmet medical needs.
Hans Clevers, PhD will be the keynote speaker and present on his work in organoids and pre-clinical models to accelerate IND enabling studies. In addition, we will be hosting the director of the Center for Biologics Evaluation and Research (CBER) at the FDA, Peter Marks, MD, PhD.
Additionally, this year's symposium seeks to highlight 2 products that were developed by the CDCM and tell the story from the bench to bedside. Alongside this year's host of renowned speakers, the stories of the gene-corrected sickle cell and epidermolysis bullosa tissue correction products will be extensively discussed.
Gene-Corrected Sickle Cell:
- Matthew Porteus, MD, PhD
- David Shyr, MD
- Jerry Cacia, CTO, Graphite Bio
- Zariah Stevenson, SCD Patient Perspective
Epidermolysis Bullosa Tissue Correction:
- Anthony Oro, MD, PhD
- Jean Tang, MD, PhD
- Michael Hund, MBA
- Charlotte Brown, EB Patient Perspective
Projected Schedule
| Opening Remarks | |
| 8:00 - 8:30 AM | Lloyd Minor, MD, Dean, School of Medicine, Stanford University |
| Paul King, President and CEO, Stanford Children's Health | |
| David Entwistle, President and CEO, Stanford Healthcare | |
| Matthew Porteus, MD, PhD, Diretor, CDCM, Stanford University | |
| Opening Keynote (Virtual) | |
| 8:30 - 9:10 AM | Keynote Speaker: Hans Clevers, MSc, MD, PhD, Head of Pharma Research and Early Development, Roche, Basel Switzerland "Organoids to Model Human Disease" |
Epidermolysis Bullosa Tissue Correction Therapy Panel Moderator: Rosa Bacchetta |
|
| 9:15 - 10:30 AM | Anthony Oro, MD, PhD, Associate Director, CDCM, Stanford University |
| Jean Tang, MD, PhD, Professor of Dermatology, Stanford University | |
| Michael Hund, MBA, CEO, EB Research Partnership | |
| Charlotte Brown (Patient Perspective) | |
| 10:30 - 11:00 AM | Break |
From Discovery to Translation Moderator: Katja Weinacht |
|
| 11:00 - 11:25 AM | Euan Ashley, PhD, Associate Dean, Roger and Joelle Burnell Professor of Genomics and Precision Health "Precision Diagnostics for Precision Therapeutics" |
| 11:25 - 11:50 AM | Tushar Desai, MD, Robert A. and Gertrude T. Hudson Professor of Pulmonary, Allergy & Critical Care Medicine, ISCBRM, Stanford University "Stem Cell Transplantation for Refractory Cystic Fibrosis Sinus Disease: Status Update and Emerging Questions" |
| 11:50 - 12:15 PM | Tippi Mackenzie, MD, Director, The Eli and Edythe Broader Center of Regeneration Medicine and Stem Cell Research, UCSF "Fetal Therapies for Single Gene Disorders" |
| 12:15 - 12:40 PM | Melody Smith, MD, Assistant Professor, Division of Blood & Marrow Transplantation and Cellular Therapy, Stanford University "Donor CAR T Cell Therapy Following Allogenic Hematopoetic Stem Cell Transplantation as a strategy to Decrease Disease Relapse" |
| 12:40 - 1:45 PM | Lunch Break/Sponsor Presentations |
Translational Partnerships Moderator: Fraser Wright |
|
| 1:45 - 2:10 PM | Neehar Bhatia Memorial Lecture: Mohamed Abou-el-Enein, MD, PhD, MSPH, Executive Director, USC/CHLA Cell Therapy Program "From Concept to Reality: Establishing a Successful Cell Therapy Ecosystem at USC" |
| 2:10 - 2:35 PM | Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA "FDA's Regulatory Framework for Cell and Gene Therapies" |
| 2:35 - 3:00 PM | Bill Lis, Chairman, Jasper Therapeutics Inc; Director, Zai Laboratories Inc; Operating Executive, Abingworth Ventures "Academic - Industry Collaboration: A Lifeblood of Therapeutic Innovation" |
| 3:00 - 3:30 PM | Break |
Gene-Corrected Sickle Cell Therapy Panel Moderator: Natalia Gomez-Ospina |
|
| 3:30 - 4:45 PM | Matthew Porteus, MD, PhD, Director, CDCM, Stanford University |
| David Shyr, MD, Clinical Assistant Professor of Pediatrics, Stem Cell Transplantation, Stanford University | |
| Jerry Cacia, CTO, Graphite Bio | |
| Zariah Stevenson (Patient Perspective) | |
| Closing Remarks | |
| 5:00 PM | Networking with Wine & Cheese |
We look forward to welcoming everyone back to an in-person and virtual format this year. If you have any questions, please contact us at:
cdcm_contact@stanford.edu